Application of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) in Alzheimer's disease

Clinical Chemistry and Laboratory Medicine

Volumn 50, Issue 8, 2012, Pages 1297-1304

  Grela, Agatha ^a   Turek, Agata ^a   Piekoszewski, Wojciech ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Alzheimer's disease; Biomarker; Matrix assisted laser desorption ionization time of flight mass spectrometry (MALDI TOF MS); Proteomics

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; ALPHA SECRETASE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; BETA SECRETASE; CHOLINESTERASE INHIBITOR; FREE RADICAL; GLYCOGEN SYNTHASE KINASE 3; MEMBRANE PROTEIN; PITTSBURGH COMPOUND B; PRESENILIN 1; PRESENILIN 2; PROTEIN KINASE C; PROTEIN PHOSPHO TAU; TAU PROTEIN; UNCLASSIFIED DRUG;

AGNOSIA; ALZHEIMER DISEASE; APHASIA; APRAXIA; BLOOD CELL COUNT; CEREBROSPINAL FLUID ANALYSIS; CHROMOSOME MUTATION; COMPUTER ASSISTED TOMOGRAPHY; DIFFUSE LEWY BODY DISEASE; HEREDITY; HUMAN; IMMUNOPRECIPITATION; INTRACELLULAR SIGNALING; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PATHOGENESIS; PEPTIDE MAPPING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEOMICS; REPRODUCIBILITY; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; HUMANS; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84867774454     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2011-0550     Document Type: Review

References (47)

1. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer Disease in the US Population. Prevalence Estimates Using the 2000 Census. Arch Neurol 2003;60:1119-22.
2. Kossowska B, Dudka I, Gancarz R, Antonowicz-Juchniewicz J. Proteomic analysis of protein profiles in some pathological stages of the human organism [review]. Postepy Hig Med Dosw (Online) 2009;63:549-63. [Polish]. Available from: www.phmd.pl.
3. Masters CL, Simm G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. P Natl Acad Sci USA 1985;82:4245-9.
4. Bartus RT, Dean III RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217:408-17.
5. Frey HJ, Mattila KM, Korolainen MA, Pirttilä T. Problems associated with biological markers of Alzheimer's disease. Neurochem Res 2005;30:1501-10.
6. Humpel C. Identifying and validating biomarkers for Alzheimer's disease. Trends Biotechnol 2011;29:26-32.
7. Dmitrzak-Wȩglarz M, Hauser J. Proteomic analysis in quest for biologic markers of psychiatric diseases. Psychiatria 2006;3:118-27.
8. Castellani RJ, Rolston RK, Smith MA. Alzheimer disease. Dis Mon 2010;56:484-546.
9. Braak H, Braak E. Neuropathological stageing of Alzheimerrelated changes. Acta Neuropathol 1991;82:239-59.
10. Robakis NK. Mechanisms of AD neurodegeneration may be independent of Aβ and its derivatives. Neurobiol Aging 2011;32:372-9.
11. Parihar MS, Hemnani T. Alzheimer's disease pathogenesis and therapeutic interventions. J Clin Neurosci 2004;11:456-67.
12. Hollingworth P, Harold D, Jones L, Owen MJ, Williams J. Alzheimer's disease genetics: current knowledge and future challenges. Int J Geriatr Psych 2011;26:793-802.
13. Prvulovic D, Hampel H. Amyloid β (Aβ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease. Clin Chem Lab Med 2011;49:367-74.
14. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack Jr CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging. Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:263-9.
15. Hort J, O'Brien JT, Gainotti G, Pirttila T, Popescu BO, Rektorova I, et al. EFNS guidelines for the diagnosis and management of Alzheimer's disease. Eur J Neurol 2010;17:1236-48.
16. Klunk WE, Mathis CA. The future of amyloid-beta imaging: a tale of radionuclides and tracer proliferation. Curr Opin Neurol 2008;21:683-7.
17. Kroksveen AC, Opsahl JA, Aye TT, Ulvik RJ, Berven FS. Proteomics of human cerebrospinal fluid: discovery and verification of biomarker candidates in neurodegenerative diseases using quantitative proteomics. J Proteomics 2011;74:371-88.
18. Whiley L, Legido-Quigley C. Current strategies in the discovery of small-molecule biomarkers for Alzheimers disease. Bioanalysis 2011;3:1121-42.
19. Pesaresi M, Lovati C, Bertora P, Mailland E, Galimberti D, Scarpini E, et al. Plasma levels of beta-amyloid (1-42) in Alzheimer's disease and mild cognitive impairment. Neurobiol Aging 2006;27:904-5.
20. Blennow K, Zetterberg H. Use of CSF biomarkers in Alzheimer's disease clinical trials. J Nutr Health Aging 2009;13:358-61.
21. Skoog I, Davidsson P, Aevarsson Ó, Vanderstichele H, Vanmechelen E, Blennow K. Cerebrospinal fluid betaamyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds. Dement Geriatr Cogn 2003;15:169-76.
22. Gustafson DR, Skoog I, Rosengren L, Zetterberg H, Blennow K. Cerebrospinal fluid β-amyloid 1-42 concentration may predict cognitive decline in older women. J Neurol Neurosur Ps 2007;78:461-4.
23. Mattsson N. CSF biomarkers in neurodegenerative diseases. Clin Chem Lab Med 2011;49:345-52.
24. Parnetti L, Lanari A, Amici S, Gallai V, Vanmechelen E, Hulstaert F. CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Neurol Sci 2001;22:77-8.
25. Kasuga K, Tokutake T, Ishikawa A, Uchiyama T, Tokuda T, Onodera O, et al. Differential levels of a-synuclein, β-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease. J Neurol Neurosur Ps 2010;81:608-10.
26. German DC, Gurnani P, Nandi A, Garner HR, Fisher W, Diaz-Arrastia R, et al. Serum biomarkers for Alzheimer's disease: proteomic discovery. Biomed Pharmacother 2007;61:383-9.
27. Maddalena A, Papassotiropoulos A, Müller-Tillmanns B, Jung HH, Hegi T, Nitsch RM, et al. Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to β-amyloid peptide42. Arch Neurol 2003;60:1202-6.
28. Maji SK, Anoop A, Singh PK, Jacob RS. CSF biomarkers for Alzheimer's disease diagnosis. Int J Alzheimer's Dis 2010;2010. doi:10.4061/2010/606802.
29. Schipper HM. The role of biologic markers in the diagnosis of Alzheimer's disease. Alzheimers Dement 2007;3:325-32.
30. Schipper HM. Biological markers and Alzheimer disease: a Canadian perspective. Int J Alzheimers Dis 2010;2010. doi: 10.4061/2010/978182.
31. Wahlund L-O, Blennow K. Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients. Neurosci Lett 2000;339:99-102.
32. De Barry J, Liégeois CM, Janoshazi A. Protein kinase C as a peripheral biomarker for Alzheimer's disease. Exp Gerontol 2010;45:64-9.
33. Thambisetty M, Tripaldi R, Riddoch-Contreras J, Hye A, An Y, Campbell J, et al. Proteome-based plasma markers of brain amyloid-β deposition in non-demented older individuals. J Alzheimers Dis 2010;22:1099-109.
34. Portelius E, Dean RA, Gustavsson MK, Andreasson U, Zetterberg H, Siemers E, et al. A novel A β isoform pattern in CSF reflects?-secretase inhibition in Alzheimer disease. Alzheimers Res The 2010;2:7.
35. Portelius E, Price E, Brinkmalm G, Stiteler M, Olsson M, Persson R, et al. A novel pathway for amyloid precursor protein processing. Neurobiol Aging 2011;32:1090-8.
36. Villemagne VL, Perez KA, Pike KE, Kok WM, Rowe CC, White AR. Blood-borne amyloid-β dimer correlates with clinical markers of Alzheimer's disease. J Neurosci 2010;30:6315-22.
37. Perrin RJ, Craig-Schapiro R, Malone JP, Shah AR, Gilmore P, Davis AE, et al. Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease. PLoS ONE 2011;6:e16032.
38. Cohen TJ, Guo JL, Hurtado DE, Kwong LK, Mills IP, Trojanowski JQ, et al. The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat Commun 2011;2:252.
39. Min S-W, Cho S-H, Zhou Y, Schroeder S, Haroutunian V, Seeley WW, et al. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron. 2010;67:953-66.
40. Villar-Garea A, Griese M, Imhof A. Biomarker discovery from body fluids using mass spectrometry. J Chromatogr B 2007;849:105-14.
41. Portelius E, Zetterberg H, Gobom J, Andreasson U, Blennow K. Targeted proteomics in Alzheimer's disease: focus on amyloid-β. Expert Rev Proteomic 2008;5:225-37.
42. Vigo-Pelfrey C, Lee D, Keim P, Lieberburg I, Schenk DB. Characterization of β-amyloid peptide from human cerebrospinal fluid. J Neurochem 1993;61:1965-8.
43. Grasso G. The use of mass spectrometry to study amyloid-β peptides. Mass Spectrom Rev 2011;30:347-65.
44. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002;1:845-67.
45. Van der Merwe D, Oikonomopoulou K, Marshall J, Diamandis EP. Mass spectrometry: uncovering the cancer proteome for diagnostics. Adv Cancer Res 2006;96:23-50.
46. Villanueva J, Philip J, Chaparro CA, Li Y, Toledo-Crow R, De Noyer L, et al. Correcting common errors in identifying cancer-specific serum peptide signatures. J Proteome Res 2005;4:1060-72.
47. Liland KH, Mevik BH, Rukke EO, Almøy T, Skaugen M, Isaksson T. Quantitative whole spectrum analysis with MALDI-TOF MS, Part I: measurement optimisation. Chemometr Intell Lab 2009;96:210-8.